Grant Details
Funder: NIMH
Grant Number: U19MH121738-02S2 (supplement to main MHRN cooperative agreement)
Grant Period: 9/17/2020 – 8/31/2022
Narrative: This large observational study will evaluate the effects of initiating buprenorphine treatment on subsequent suicidal behavior among people with opioid use disorder, including those with and without co-occurring mental health conditions or other known risk factors for suicidal behavior. We will use comprehensive health records data from four large health systems serving a combined member/patient population of approximately 11 million. Analyses will examine the overall effect of buprenorphine treatment on subsequent suicide attempts or death, heterogeneity of effects in patient subgroups, and specificity of effects to buprenorphine vs other medications.
- Lead Site: KPWA
- Overall PI: Greg Simon
- Lead Project Manager: Erika Holden
- Participating Sites/Subcontractors:
- KPNC – Site PI: Cynthia Campell
- KPSC – Site PI: Rulin Hechter
- Henry Ford – Site PI: Brian Ahmedani
- Funder Contacts:
- Science Officer: Susan Azrin
- Program Official: Michael Freed
- Grants Management Official: Julie Bergerud
- Awarded Budget (Total Cost):
- Year 1: $514,616
- Year 2: $274,321
Documents & Reports
Funding Announcement: PA-18-591
- Submitted Proposal
Planned inclusion/enrollment report
Most recent inclusion/enrollment report
- Notices of Award:
Contracts:
Personnel Contact List
Human Subjects: YES
- IRB Review:
- KPWA is single IRB reviewing for KPWA, KPNC, and KPSC – Approved waiver of consent for use of records data
- Henry Ford determined to be exempt
- KPWA IRBnet File: [1649129] Buprenorphine Effect on Suicidal Behavior
Clinical Trial: NO
Publications
Change Request Form
See something that needs to be changed? Complete the form below to submit your request.